Chemoimmunotherapy: still waiting for the magic to happen
Mené au Royaume-Uni sur 1 062 patients atteints d'un cancer du pancréas localement avancé ou métastatique, cet essai multicentrique de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout d'un vaccin anti-télomérase (GV1001) à une chimiothérapie combinant gemcitabine et capécitabine
Over the past 10 years, there has been mainstream acceptance that some chemotherapies can be combined with immunotherapy in murine models, combining synergistically to lead to an improved outcome. What has proven more difficult is translating that knowledge to positive, practice-changing clinical trials. The TeloVac investigators did a large three-arm randomised phase 3 trial, investigating a telomerase peptide vaccine plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination ...
The Lancet Oncology , commentaire, 2013